News
11-23-2009, 05:50 AM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.
More... (http://www.news-medical.net/news/20091123/Provectus-Pharmaceuticals-announces-Phase-1-interim-study-data-of-PV-10-for-metastatic-melanoma.aspx)
More... (http://www.news-medical.net/news/20091123/Provectus-Pharmaceuticals-announces-Phase-1-interim-study-data-of-PV-10-for-metastatic-melanoma.aspx)